Error message

No crossref credentials set for sci

The Adjuvant Effects of Antibodies

Science, 19 August 2011
Vol. 333, Issue 6045, p. 944-945
DOI: 10.1126/science.1210801

The Adjuvant Effects of Antibodies

  1. Mark J. Smyth,
  2. Michael H. Kershaw
  1. Cancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, 3002 Victoria, Australia. University of Melbourne, 3010 Victoria, Australia.
  1. E-mail: mark.smyth{at}


Monoclonal antibodies (mAbs) are perhaps the most exciting, specific, and flexible vehicle for treating cancer. Major leaps in the engineering of mAbs over the past three decades have improved their effectiveness against target antigens. CD40, a member of the tumor necrosis factor receptor (TNFR) superfamily expressed on antigen-presenting cells, is one such target, but so far the clinical efficacy of a mAb against this molecule in cancer patients has been limited. On page 1030 of this issue, Li and Ravetch (1) demonstrate that a mAb to CD40, with enhanced binding to another protein on antigen-presenting cells, increases activation of the antigen-presenting cells and thereby promotes an adaptive immune response. This has implications for the design of other therapeutic mAbs.


M. J. Smyth and M. H. Kershaw, The Adjuvant Effects of Antibodies. Science 333, 944-945 (2011).

Fc{gamma} Receptor Dependency of Agonistic CD40 Antibody in Lymphoma Therapy Can Be Overcome through Antibody Multimerization
A. L. White, L. Dou, H. T. C. Chan, V. L. Field, C. I. Mockridge, K. Moss, E. L. Williams, S. G. Booth, R. R. French, E. A. Potter et al.
J. Immunol. 193, 1828-1835 (15 August 2014)

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882